Browsing Tag
CAR T therapy
3 posts
Can in vivo CAR T therapies expand access beyond specialized treatment centers
Explore how CPTx’s in vivo CAR T strategy could lower costs, simplify delivery, and expand access beyond specialized cancer treatment centers.
Analysts weigh Bristol Myers Squibb’s $1.5bn Orbital Therapeutics deal as a bold but risky pivot
Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics aims to advance in vivo CAR T for autoimmune diseases and strengthen its RNA platform.
Bristol Myers Squibb Gains U.S. FDA Approval to Remove REMS Programs and Ease Monitoring Rules for Breyanzi and Abecma Cell Therapies
Bristol Myers Squibb gains U.S. FDA approval to remove REMS and reduce monitoring for Breyanzi and Abecma cell therapies, expanding access for blood cancer patients.